Durable Response of Metastatic Tumor to Erlotinib and Capecitabine in a Patient with Pancreatic Adenocarcinoma
Other Title
對得舒緩和截瘤達有耐久性反應的胰臟癌
Journal
台灣癌症醫學雜誌
Journal Volume
29
Journal Issue
3
Pages
155
Date Issued
2013-08-01
Author(s)
Jo-Pai Chen
Abstract
Pancreatic adenocarcinoma with distant metastases is an extremely challenging diagnosis. We report on a 74-year-old man with early stage lung cancer who had previously received a curative operation. Subsequent pancreatic cancer developed one year later. A curative operation for pancreatic cancer was then performed, but rapid tumor recurrence with multiple metastatic sites were identified soon after the operation. The patient was treated with several lines of chemotherapy but progressive disease persisted until erlotinib-combined chemotherapy was undertaken. Then the patient maintained a durable response to erlotinib and capecitabine for nearly 2 years. We reviewed the relationship between K-RAS mutation and the efficacy of erlotinib on pancreatic adenocarcinoma.
Subjects
pancreatic adenocarcinoma
erlotinib
K-RAS
SDGs
Type
journal article